Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
PEGylation technology: addressing concerns, moving forward |
| Συγγραφείς: |
Simberg D, Barenholz Y, Roffler SR, Landfester K, Kabanov AV, Moghimi SM |
| Πηγή: |
Drug Delivery, 2025 |
| Στοιχεία εκδότη: |
Taylor and Francis Ltd. |
| Έτος έκδοσης: |
2025 |
| Συλλογή: |
Newcastle University Library ePrints Service |
| Περιγραφή: |
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.PEGylation technology, that is grafting of poly(ethylene glycol)(PEG) to biologics, vaccines and nanopharmaceuticals, has become a cornerstone of modern medicines with over thirty products used in the clinic. PEGylation of therapeutic proteins, nucleic acids and nanopharmaceuticals improves their stability, pharmacokinetic and biodistribution. While PEGylated medicines are safe in the majority of patients, there are growing concerns about the emergence of anti-PEG antibodies and their impact on the therapeutic efficacy of PEGylated medicines as well as broader immune responses, particularly in complement activation and hypersensitivity reactions. These concerns are beginning to scrutinize the future viability of PEGylation technology in medicine design. Here, we outline these concerns, encourage more efforts into looking for comprehensive scientific evidence on the role of anti-PEG antibodies in hypersensitivity reactions, discuss alternatives to PEG and propose strategies for moving PEGylation technology forward. |
| Τύπος εγγράφου: |
Thesis |
| Περιγραφή αρχείου: |
application/pdf |
| Γλώσσα: |
unknown |
| Relation: |
https://eprints.ncl.ac.uk/305680; https://eprints.ncl.ac.uk/fulltext.aspx?url=305680/36B891D9-1469-4C1D-BF35-86A429428CDB.pdf&pub_id=305680 |
| Διαθεσιμότητα: |
https://eprints.ncl.ac.uk/305680 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Αριθμός Καταχώρησης: |
edsbas.69AC3B48 |
| Βάση Δεδομένων: |
BASE |